Noom Launches Microdose GLP-1 Program, Enabling Weight Loss Without the Side Effects and Priced at $119 to Start, Including Medication and Microhabits Program
The program addresses all three major barriers to bending the obesity curve in the US: excessive US prices of medication, medication side effects, and sustainable lifestyle change
NEW YORK, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Noom, the leading digital healthcare company committed to chronic disease prevention and empowering people to live better longer, today announced the launch of the Noom Microdose GLP-1Rx Program, a groundbreaking offering designed to unlock weight loss and long-term health benefits while minimizing side effects through personalized microdoses of GLP-1 medication, when clinically appropriate. The Microdose GLP-1Rx Program is priced at $119 to start, followed by $199 per month, which includes medication, if prescribed, and Noom's powerful GLP-1 Companion, providing clinical care, coaching, and a personalized healthy habits program.
The US obesity rate, after decades of unstoppable growth, has at last started to plateau, but at a level that continues to lead the developed world. The US rate of obesity stands at more than 40% versus the UK at 26%, Germany at 23%, and France at 10%. Meanwhile, GLP-1 medications cost as much as 5x more in the US than in these same countries. Three core barriers prevent broader and faster progress: medication cost, medication side effects, and the lack of sustainable behavior change. Noom's Microdose GLP-1Rx Program directly addresses each of these three barriers, to help meaningfully bend the obesity curve.
Only affordable GLP-1s and Behavior Change will bend this curve.
Noom's physician-designed program employs a 'low and slow' titration approach with microdoses that are a fraction of conventional maintenance doses. Noom's data has shown that members on microdoses are far less likely to have destabilizing side effects. In fact, 70% of Noom members receiving microdoses report no side effects at all. At the same time, members achieve up to 11 pounds of weight loss in 30 days and up to 17 pounds in 60 days at microdose dosages. Meanwhile, studies indicate the vast majority–more than 70%–of patients on standardized protocols experience side effects.
'In the Microdose GLP-1Rx Program, we set out to virtually eliminate side effects for the vast majority, so that more than 70% of people would encounter no side effects. In both my clinical experience and evidence in published studies, it is clear that many people discontinue GLP-1 treatment because of side effects,' said Dr. Jeffrey Egler, Chief Medical Officer at Noom. 'The Noom Microdose GLP-1Rx Program was designed to address this issue by introducing GLP-1s gradually and sustaining them at a microdose level, as part of a larger holistic behavior change platform, which we call our GLP-1 Companion. This approach helps more patients stay on the treatment, experience the full health benefits of these medications, and make real progress in reducing obesity and overweight rates in the United States.'
Noom's Microdose GLP-1Rx Program is based on scientific principles:
Self-efficacy boosts success with healthy habits. GLP-1 medication makes it easier to adopt healthy habits, while healthy habits improve health outcomes. Members who engage with Noom's GLP-1 Companion achieve 10% weight loss by month 4 at twice the rate compared to those who are not engaged. Noom members on GLP-1s actually log more meals, weigh in more often, and log more exercise by their second month than those on Noom without a GLP-1.
Strong weight loss outcomes at lower doses are both achievable and well established in the literature. A 2,700‑person real‑world study presented at the 2025 European Congress on Obesity showed an average 16% weight‑loss over 64 weeks at microdose levels of semaglutide. Meanwhile, another study in The New England Journal of Medicine shows just 33% of the dose of one popular GLP-1 drove 72% of the weight loss at week 72 with a lower side effect profile.
The benefits from GLP-1s extend beyond weight. Recent analyses presented at the National Lipid Association's 2025 Scientific Sessions highlighted cardiovascular, renal, and metabolic gains from GLP‑1s that appear partly independent of the amount of weight loss. Other studies show a similar impact on inflammatory markers independent of weight loss.. Meanwhile, other studies demonstrate a reduction in compulsive behaviors like drinking and gambling.
Taken together, the evidence is clear: microdoses of GLP-1 paired with microhabits can unlock outsized health benefits.
What is a Microdose?
Noom defines a microdose as a dose of medication that is a fraction – 25% or less – of the typically prescribed maintenance dose. Noom's microdose dosing schedule is not one-size-fits-all. It accesses doses lower than the usual starter doses as well as additional doses up to 25% of the standard maintenance dose.
Within that band, the exact dosage schedule is established one member at a time: our physician-prescribed protocol, aided by Noom's SmartDose experience, guides members to the lowest dose that achieves health goals. Factors influencing that decision include BMI, weight loss speed, side effect profile, and other health data.
'Noom has a unique, proprietary dataset that permits the level of deep personalization that our program deploys,' continued Dr. Jeffrey Egler. 'The Noom program has comprehensive data on patient health, injection dates, side effects, and weight-loss speed, and we bring that data to bear to personalize the dosing to maximize outcomes and adherence not just to the medication, but to our Noom microhabits program.'
While many eligible GLP-1 users are deterred from starting medication due to fear of incurring side effects, others are challenged by high medication costs. Among those who do start using GLP-1s, over 50% stop due to costs, and as many as 36% stop due to side effects.
Noom's Microdose GLP-1Rx Program bridges this gap by offering a more personalized, tolerable path to treatment. It is built on a guiding principle of using the lowest effective dose first. Rather than increasing medication on a fixed schedule, Noom's physician-designed protocol adjusts dosing based on each patient's individual progress and response. This approach enables personalized care that supports meaningful weight loss while minimizing side effects and helping more people adhere to the treatment.
GLP-1s and Weight Loss Accessibility - Solving Today's High-Priced Drug Crisis
GLP-1 medications continue to be significantly more affordable around the world than in the United States. Popular GLP-1 medications are priced around $99 a month in many developed nations, but at $499 a month to cash-pay patients in the United States. Cost is a major barrier to accessibility in the US, where the price of medications and healthcare services are often much higher than internationally.
Noom's accessibly priced Microdose GLP-1Rx Program, starting at $119, builds on the company's advocacy efforts on behalf of patients in the US. In April 2025, Noom sponsored a back cover advertisement in the The Wall Street Journal calling for the creation of a High-Priced Drug List by HHS. The High-Priced Drug List is a market-based solution enabling competition from the country's 503A and 503B pharmacies when medications are priced higher in the United States compared to other developed countries.
In addition to the launch of Noom's Microdose GLP-1Rx Program, on Wednesday, July 30th, at an event at The White House, Noom pledged to make available a free tier of Noom to all Americans – regardless of income or BMI. The free tier will launch before the end of the summer and deliver a personalized experience focused on building healthy habits in nutrition, physical activity, and stress reduction. 'Medication alone will not end the obesity epidemic. Lifestyle change is essential,' said Cook. 'By offering a no-cost way for anyone to build healthy habits with Noom, we can reach millions more Americans with the tools to help them live better longer. Pairing that with our new microdose GLP-1 program will help bend the curve on obesity rates in the United States.'
Noom Microdose GLP-1Rx Program includes:
Microdose GLP-1 medication, if prescribed
Full access to the Noom GLP-1 Companion behavior and microhabits program
24/7 access to message doctors and care coordinators
Noom premium 1:1 health coaching
Prescription home delivery
Pricing: $119 to start and then $199 per month
Looking Ahead to Longevity
'GLP-1s with Noom's microhabit program represent a modern treatment for the ills of modernity,' said Cook. 'We help people sustain a healthy weight in a food environment engineered for dopamine-hits and excess consumption. By helping people limit compulsive eating and drinking, motivate movement, and reduce chronic inflammation, which we know GLP-1s can do, we promote a higher quality life.'
'The latest science demonstrates that we should be thinking about GLP-1 medication differently,' said Dr. Jeffrey Egler. 'GLP-1s are no longer only useful for weight loss and diabetes – they are critical for building metabolic resilience and reducing inflammation, making them a powerful component of whole-person, lasting health. For our patients, we see GLP-1s as the first step in an extraordinary journey to true vitality.'
The Microdose GLP-1Rx Program is available to Americans in 45 states at the following link: https://www.noom.com/med/glp1-microdose/
About Noom:
Noom is the leading whole-person health platform, combining personalized medication with psychology and habit science to help people take control of their metabolic health, weight, and longevity. Noom Health partners with top health plans and employers to offer a suite of solutions, including Noom Med, Noom Weight, Noom GLP-1 Companion, and Noom Diabetes Management and Diabetes Prevention Program to millions.
Founded on a mission to empower everyone everywhere to live better longer, Noom has received multiple National Institute of Health grants and was the first mobile app recognized by the CDC as a certified diabetes prevention program. With offices in New York City and Princeton, NJ, Noom has been named one of Inc.'s Best Places to Work, Quartz's Best Workplaces for Remote Workers, and Fortune's Best Workplaces in Technology.
Learn more at noom.com, subscribe to our blog, or follow us on Twitter and LinkedIn.
Contact:Brandyn Bissingercomms@noom.com
Photos accompanying this announcement are available at:
https://www.globenewswire.com/NewsRoom/AttachmentNg/11635e70-9ac6-4fe7-b895-3899e981ff68
https://www.globenewswire.com/NewsRoom/AttachmentNg/4a772c14-c2b2-4568-bf2b-222ab87777f3Fehler beim Abrufen der Daten
Melden Sie sich an, um Ihr Portfolio aufzurufen.
Fehler beim Abrufen der Daten
Fehler beim Abrufen der Daten
Fehler beim Abrufen der Daten
Fehler beim Abrufen der Daten
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
38 minutes ago
- Yahoo
"Never Has America Been More Vulnerable" — People Are Horrified After RFK Jr. Announced He's Cutting $500 Million In Funding For mRNA Vaccines
I'm not sure if you've heard, but everyone's least favorite Health and Human Services Secretary, RFK Jr., recently announced that he's canceling $500 million in funding for mRNA vaccine development. mRNA vaccines, which stand for messenger ribonucleic acid (RNA), are "highly effective" and "safe," according to the National Council on Aging, a nonprofit organization that works to improve the health of older adults in the US. According to the Cleveland Clinic, the mRNA vaccine helps teach your body to fight infectious diseases. More specifically, mRNA technology is utilized in the COVID-19 vaccine, which infectious disease experts say is what helped to slow the 2020 COVID-19 outbreak in the US. In a now-viral X video, RFK Jr. tried to explain the funding cuts saying, "HHS has determined that mRNA technology poses more risk than benefits for these respiratory viruses." Twitter: @SecKennedy According to CBS News, RFK Jr. reiterated that "HHS supports safe, effective vaccines for every American who wants them." Related: In response to the news, Mike Osterholm, a University of Minnesota expert on infectious diseases and pandemic preparations, recently said it's "one of the worst decisions I've seen in 50 years of public health preparedness work." Following these vaccine funding cuts, millions have expressed deep concern for the future of medicine, as well as the impact of future pandemics in the US. Here's how medical professionals, lawmakers, and citizens are reacting: Commonly, people threw some personal digs at RFK Jr., with one person calling him a "despicable quack." ...and a pediatric MD calling him an "anti-vaxx weirdo." Related: While other medical professionals directly contradicted RFK Jr.'s claims about the mRNA vaccine, calling them "simply false." And called out RFK Jr.'s "fundamental misunderstanding of immunology." Another infectious disease doctor argued that RFK Jr.'s decision came from "ideology" and "online anti vax talking points." Related: And this medical professional and health writer called mRNA vaccines "one of the most important tools we have for preventing future pandemics." Another person expressed their anger about "throwing away" years of research: Even politicians have weighed in, with Senator Reverend Raphael Warnock calling the funding cuts a "tragedy." Related: "Whatever your reason for not voting or voting 3rd party, I promise it wasn't worth destroying our country over," this person wrote. And this person made a scary observation, writing: "A diseased population is easier to control..." And finally, this Reddit user summed up what many are feeling: "Imagine being so privileged to have lived in a tiny slice of human history when MILLIONS of people have been spared from pyrogens at the hands of vaccines……only to be somehow convinced the answer to the threat humanity faces going forward is to stop researching the most proven and effective medicine mankind has ever known." What are your thoughts? Let us know in the comments below. Also in In the News: Also in In the News: Also in In the News:
Yahoo
40 minutes ago
- Yahoo
Venus Williams Exposed Health Insurance Defects
Venus Williams returned to professional tennis due to insurance reasons, citing her need to pay for COBRA, a federal law that allows individuals to temporarily continue their employer-sponsored health insurance. The US system of health insurance is built on employer-sponsored coverage, which has "scant labor market or health justification" and is driven by "entrenched interests" rather than producing good health outcomes. Bloomberg's Kathryn Anne Edwards has more on the story.
Medscape
an hour ago
- Medscape
Even Low Lead Exposure Can Impair Academic Outcomes in Kids
TOPLINE: Every 1-unit increase in blood lead levels in early childhood — even when below the 'safe' threshold of 3.5 µg/dL — was associated with declines in math and reading scores from grades 2 through 11, similar to those seen at higher lead levels. METHODOLOGY: Researchers used the 2021 US CDC's revision of the blood lead reference value to ≥ 3.5 μg/dL. They analyzed data from birth certificates of children born in Iowa from 1989 to 2010, academic test scores from grades 2 through 11, and blood lead testing data from 1990 to 2017. The analysis included 305,256 children (mean age at lead testing, 1.9 years; 49% girls) and nearly 1.8 million math and reading scores to calculate the national percentile rank (NPR). Primary outcomes included NPR scores across grades 2 through 11, comparing children with blood lead levels < 3.5 μg/dL with those at or above this threshold. TAKEAWAY: Overall, 37.7% of children had lead levels < 3.5 μg/dL. Among children with blood lead levels < 3.5 μg/dL, a 1-unit increase was associated with lower NPR scores in math (-0.47; 95% CI, -0.65 to -0.30) and in reading (-0.38; 95% CI, -0.56 to -0.20). Similarly, for lead levels at ≥ 3.5 μg/dL, every 1-unit increase was linked to a significant decline in NPR scores for math and reading. The trend of declining scores with increasing lead levels was persistent across grades 2 through 11; only the declines in reading scores for grades 10 and 11 were not statistically significant. IN PRACTICE: 'The present work provides further evidence to support that there are no safe levels of lead and that there is a need to continue to reduce or eliminate lead exposure,' the authors of the study wrote. SOURCE: This study was led by George L. Wehby, MPH, PhD, of the Department of Health Management and Policy at the University of Iowa in Iowa City, Iowa. It was published online on May 28, 2025, in JAMA Network Open. LIMITATIONS: Several laboratories used the old 5 μg/dL cutoff to quantify high lead levels. Researchers lacked data on any lead-related interventions the children may have received. DISCLOSURES: Wehby reported receiving grants from the Gates Foundation during the conduct of this study. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
